Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.
Zacks
More News
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.
Zacks
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate...
CNBC: Top News
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
Key PointsPfizer aims to enter the weight loss drug market, and one platform should be the workhorse of this effort...
Nasdaq News: Markets
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.
Zacks
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $43.93, denoting a +2.62% move from the preceding trading day.
Zacks
NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News
Novo Nordisk revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Wegovy pill, following in the footsteps of the U.S. FDA.
Stocktwits
Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
Novo Nordisk wins U.K. approval for Wegovy pill, offering adults a daily oral weight-loss option backed by Phase 3 trial data.read more...
Benzinga
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
Can Amgen's MariTide Win Share in the Fast-Growing Obesity Market?
MariTide's less frequent dosing could help AMGN carve out a place in the rapidly expanding obesity drug market.